Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSI-195 as add-on therapy for Major Depressive Disorder
NCT01912196Phase 2Completed
- Sponsor
- MSI Methylation Sciences
- Start
- Oct 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of S-adenosylmethionine in major depressive disorder (MDD), sponsored by MSI Methylation Sciences. Started Oct 2013; status: completed.
02
Drugs
S-adenosylmethionine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01912196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01912196.